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Abstract  The  indications,  technique,  results  and  limitations  of  MRI  vacuum-assisted  breast
biopsies are  discussed  from  a  review  of  the  literature.  This  was  initially  a  home-grown  tech-
nique and  its  development  was  slowed  down  by  several  factors.  As  a  result  of  major  technical
advances, it  has  become  a  reliable  and  very  consistent  procedure  with  a  low  rate  of  underes-Targeted  ultrasound;
Second  look
examination
timation. It  is  now  an  undisputed  technique  when  suspicious  MRI  enhancement  is  seen  with  no
corresponding  mammography  or  ultrasound  features.
© 2013  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
Introduction
Breast  MRI  developed  in  the  1980s.  It  is  a second  look  examination  although  the  devel-
opment  of  screening,  patient  and  media  demand  and  improved  access  to  machines  have
promoted  the  widespread  use  of  the  technique.
It  offers  excellent  sensitivity,  on  average  of  0.9  (0.88—0.92)  [1]  and  can  identify  occult
inﬁltrative  cancers  under  a  centimeter  in  size  (when  clinical  examination,  mammography
and  ultrasound  are  normal).
It  has  an  average  speciﬁcity  of  0.72  (0.67—0.77)  [1],  which  depends  greatly  on  the
indications.  These  are  now  well  deﬁned  [2].
Even  if  these  indications  and  technical  quality  criteria  are  followed  however,  contrast
enhancement  suspected  of  being  malignant  can  only  be  conﬁrmed  histologically.
MRI-guided  preoperative  localization  [3—9]  and  sampling  (ﬁne  needle  aspiration  cytolo-
gies,  core  biopsies  [8,10]  and  then  vacuum-assisted  breast  biopsies  [11—13]) have  therefore
been  developed.
Abbreviations: MRI, magnetic resonance imaging; CE, contrast enhancement; BI-RADS, breast imaging reporting system and data system;
HRT, hormone replacement therapy; PPV, positive predictive value; NPV, negative predictive value; MDT, multidisciplinary team meeting;
T, tesla; G, gauge (cannula diameter); CAD, computer-assisted diagnosis; HAS, Haute Autorité de santé (French National Health Authority);
ADH, atypical ductal hyperplasia; DCIS, ductal carcinoma in situ; Vs, versus.
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[80  
argeted examinations
hen  suspicious  CE  (BI-RADS  4  or  5  or  even  3)  is  found
n  a  breast  MRI  performed  for  a  recognized  indica-
ion  [14]  and  no  corresponding  abnormalities  are  present
n  a  conventional  assessment,  the  average  malignancy
ate  is  30%  (20  to  62%,  depending  on  recruitment  type)
15—24].
This  ﬁgure  increases  with  the  size  of  the  area  of  enhance-
ent  (3%  for  <  5  mm  versus  31%  for  >  20  mm)  [24]  and  is
eported  to  be  greater  if  a  corresponding  mammogra-
hy  or  ultrasound  abnormality  is  present  [15,21,22,35—37]
Table  1).
Targeted  investigations  (mammography  and/or  ultra-
ound)  are  then  performed  in  order  to  investigate  for  an
ccasionally  subtle  abnormality,  which  is  not  seen  on  the
nitial  breast  assessment  [22].
Ideally,  this  is  performed  by  the  radiologist  who  carried
ut  the  MRI.  If  not,  the  radiologist  who  does  carry  out  the
nvestigation  should  have  access  to  all  of  the  information,
.e.  all  of  the  images  written  to  CD,  the  site  on  a  topogram,
econstructions  (MIP,  MPR)  and  distances  from  the  various
andmarks  [46—49].
The  radiologist  needs  to  know  the  shape  of  the  CE  and
ake  account  of  its  change  in  position  between  MRI  and
ammography  or  ultrasound  and  be  aware  that  the  situa-
ion  becomes  increasingly  different  with  larger  breasts  and
he  further  away  the  CE  is  from  the  nipple,  the  only  ﬁxed
natomical  breast  landmark.
Other  landmarks  such  as  a  benign  or  cystic  tis-
ue  structure,  scar  or  macrocalciﬁcation,  etc.  can  be
sed.
Although  there  is  consensus  agreement  on  its  use,
his  guided  examination  has  not  been  carried  out  rou-
inely  [21,23,50]  or  has  not  been  described  [26]  in  some
eries.
argeted ultrasound
he  examination  needs  to  look  for  nodules,  but  also  a  poorly
elineated  area  of  tissue  (seen  particularly  in  non-mass  CE),
 complex  cyst  or  local  disharmony  (texture,  outlines  or
chogenicity).
Ultrasound  correlations  are  usually  found  in  malignancy
21,22],  mass  CE  [15,21,22,35,38,39,43,46,51], target  [39],
r  micronodular  lesions  [39],  and  BI-RADS  4  (vs  5)  [38], T2
yperintensity  or  implants.
It  is  reported  not  to  correlate  with  breast  density
15,16,39]  or  size  of  the  CE  [21,42]  as  ultrasound  resolution
s  greater  than  that  of  MRI.
Some  authors  do  report  however  that  the  correlation
s  greater  for  CE  >  10  mm  [38,39]  and  BI-RADS  5  (vs  4)
39].
It  is  described  in  61%  of  cases  (23  to  89%)  with  an  average
alignancy  rate  of  34%  (16  to  65%)  [15—22,35,38,40—45].
Nakano  [52]  greatly  improved  the  detection  rate  (90  vs
0%)  combining  ultrasound-MRI  and  image  fusion,  although
he  30%  rate  is  very  low  compared  to  other  published  stud-
es.
If  ultrasound  is  negative  (39%),  the  average  malig-
ancy  rate  falls  to  17%  (2  to  54%)  [15—22,35,38,40—45,49]
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xplaining  the  need  for  histological  proof  including  the  case
f  small  relatively  unsuspicious  CE  [43].
urther ﬁlms
n  enlarged  ﬁlm  centered  on  the  CE  quadrant  can  identify
ne  microcalciﬁcations,  which  are  not  visible  or  not  con-
idered  signiﬁcant  on  the  initial  conventional  assessment,
ogether  with  subtle  architectural  disorganization  or  local
symmetry  in  density.
These  ﬁlms  are  particularly  useful  for  non-mass  CE.
According  to  Thomassin  [36],  the  malignancy  rate  is  over
0%  in  cases  of  non-mass  enhancement  over  20  mm  in  size
ccompanied  by  microcalciﬁcations  in  the  same  area.
anagement
f  a  concordant  abnormality  is  found  the  indication  for  biopsy
s  based  on  the  worst  appearances  (MRI,  ultrasound  or  mam-
ography)  [51].
This  should  then  be  performed  stereotactically  or  under
ltrasound  guidance  as  these  are  the  most  accessible,  fast
nd  least  expensive  guidance  methods.  A  landmark  is  then
eft  in  place.
In  2005,  Taourel  [53]  proposed  labeling  the  biopsy  site
ith  in  situ  gadolinium  injection.
Currently,  however,  a  clip  is  routinely  applied
47,48,51,54]  and  the  concordant  location  of  the  CE
nd  clip  is  checked  with  a  high  TE  T1  weighted  echo
radient  MRI  image  [48,51].  Anatomical  landmarks  are  gen-
rally  sufﬁcient,  although  in  uncertain  cases  intravenous
adolinium  may  be  required.
A  repeat  MRI  after  a  short  period  of  time  (6  months)  is
ecommended  if  the  correlation  is  good  and  the  histological
esult  is  benign  [48,51].
Revision  surgery  is  required  for  a  borderline  lesion  or
arcinoma.
If  no  concordant  abnormalities  are  seen  in  a  low  risk
ituation  (when  the  indication  is  debatable  on  MRI)  and
nhancement  is  not  suspicious  [55],  a  repeat  MRI  can  be  pro-
osed  6  months  later  after  decongestant  therapy  or  stopping
RT.
In  all  of  the  other  situations  listed  below,  MRI-
uided  repeat  histology  is  required  [11,25—27,48,50,55—60]
Table  2)  (Fig.  1):
BI-RADS  3  in  women  with  mutations  or  in  ipsilateral  or
contralateral  cancer  [37,46,50,64]  as  the  PPV  of  MRI  BI-
RADS  3  is  greater  than  that  of  mammography  or  ultrasound
(<  2%)  [43,45,65];
BI-RADS  4  or  5  [11,21,26,32,33,66,67];
poor  agreement  between  CE  and  the  image  found  or  biop-
sied  on  targeted  examination  (clip  distant,  unexpected
histological  result)  [48,68].
Wherever  possible,  the  decision  is  made  following  an  MDT
50,69,70]. ‘‘Simple,  intelligible  and  reliable’’  information
s  then  given  to  the  patient  about  the  procedure,  limitations,
isks  and  the  ‘‘patient’s  free  informed  consent’’  is  obtained
ccording  to  the  terms  of  article  35  of  the  Deontology  Code
1995).
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Table  1 Results  of  the  targeted  ultrasound  after  MRI.
Authors  references Year Context  On  MRI,  number  of Number  of  2nd
look  ultrasounds
performed
On  ultrasound,  number  of  lesions
Patients Lesions  Cancers  Visible  Including
cancers
Occult  Including
cancers
La  Trenta  [15] 2003  Pre-treatment  or  follow  up 64  93  19  (20%) 93  (100%) 21  (23%) 9  (43%) 72  (77%) 10  (14%)
Deurloo  [16] 2005  Pre-treatment  assessment 48  50  20  (40%) 39  (78%) 19  (49%) 12  (63%) 20  (51%) 6  (30%)
Sim  [17] 2005  High  familial  risk 43  48  12  (25%) 48  (100%) 32  (67%) 11  (34%) 16  (33%) 1  (6%)
Beran  [18] 2005  Pre-treatment  assessment 52  73  45  (62%) 73  (100%) 65  (89%) 42  (65%) 8  (11%) 3  (35%)
Shin  [19] 2007  Pre-treatment  assessment 62  69  26  (38%) 38  (55%) 27  (71%) 15  (56%) 11  (29%) 3  (27%)
Linda  [20] 2008  Various 159  173  49  (28%) 173  (100%) 142  (82%) 46  (32%) 31  (18%) 3  (10%)
DeMartini  [21] 2009  Various 155  201  60  (30%) 167  (83%) 76  (46%) 27  (36%) 91  (54%) 20  (22%)
Carbognin  [38] 2009  Various 62  17  (27%) 62  (100%) 44  (71%) 12  (27%) 18  (29%) 5  (31%)
Meissnitzer  [39] 2009  Various 361  519  121  (23%) 519  (100%) 290  (56%) 87  (30%) 229  (44%) 34  (15%)
Destounis  [40] 2009  Pre-treatment  assessment 152  196  47  (20%) 182  (93%) 128  (70%) 39  (30%) 54  (30%) 8  (16%)
Abe  [22] 2010  Various 158  202  44  (22%) 202  (100%) 115  (57%) 33  (29%) 87  (43%) 11  (13%)
Luciani  [18] 2010  Pre-treatment  assessment 46  55  31  (56%) 55  (100%) 42  (76%) 24  (57%) 13  (24%) 7  (54%)
Candelaria  [42] 2011  Various 83  131  45  (34%) 131  (100%) 88  (67%) 27  (31%) 43  (33%) 18  (42%)
Laguna  [43]  2011  Pre-treatment  assessment  123  37  (30%)  123  (100%)  76  (62%)  26  (34%)  47  (38%)  11  (23%)
Ha  [44]  2011  Pre-treatment  assessment  33  34  7  (21%)  34  (100%)  12  (35%)  6  (50%)  22  (67%)  1  (5%)
Kim  [35]  2012  Pre-treatment  assessment  98  126  17  (13%)  126  (100%)  81  (64%)  16  (20%)  45  (36%)  1  (2%)
Fiaschetti  [45] 2012  Various 60  84  9  (11%)  84  (100%)  43  (51%)  7  (16%)  41  (49%)  2  (5%)
Total 2239  606  (37%) 2149  (96%) 1301  (61%) 439  (34%)  848  (39%)  144  (17%)
Table  2 Distribution  of  MRI-guided  vacuum-assisted  biopsies  by  morphology  and  enhancement  kinetics.
Authors
references
Year  No.  of
lesions
BI-RADS  3  BI-RADS  4  BI-RADS  5  Focus  CE-mass  CE  without  a
mass
Progressive  Plateau  Wash  out
Liberman  [25]  2005  112  3  (2.7%)  61  (54.5%)  48  (42.9%)
Lehman  [21]  2005  38  24  (66.7%)  14  (33.3%)
Gebauer  [30]  2006  42  22  (52.4%)  18  (42.9%)  2  (4.8%)  28  (66.7%)  14  (33.3%)
Lee  [29]  2007  342  21  (6.1%)  319  (93.3%)  2  (0.6%)  7  (2.1%)  167  (48.8%)  168  (49.1%)
Mahoney  [32]  2008  55  6  (10.9%)  30  (54.5%)  19  (34.5%)  17  (30.9%)  15  (27.3%)  23  (41.8%)
Hauth  [31]  2008  34  7  (20.6%)  19  (55.9%)  8  (23.5%)  23  (67.6%)  11  (32.4%)
Han  [23]  2008  150  21  (14%)  61  (40.7%)  68  (45.3%)  66  (44%)  36  (24%)  17  (11%)
Li  [61]  2009  177  98  (55.4%)  79  (44.6%)
DeMartini  [21]  2009  167  30  (18%)  84  (50.3%)  53  (31.7%)
Malhaire  [33]  2010  72  1  (1.4%)  32  (44.4%)  39  (54.2%)
Crystal  [34]  2011  26  8  (30.8%)  18  (69.2%)  14  (53.8%)  10  (38.5%)  2  (7.7%)
Zebic  [62]  2012  14  2  (14.3%)  8  (57.1%)  4  (28.6%)  5  (35.7%)  9  (64.3%)  1  (7.1%)  6  (42.9%)  7  (50%)
An  [63]  2013  15  14  (93.3%)  1  (6.7%)  13  (86.7%)  2  (13.3%)  1  (6.7%)  8  (53.3%)  6  (40%)
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ractical conditions
raining recommendations
RI-guided  biopsies  should  only  be  carried  out  in  experi-
nced  breast  centers  [50].  The  team  must  have  sufﬁcient
nd  regular  experience  in  breast  MRI  and  vacuum-assisted
iopsy  (over  50  procedures  annually)  [50,64,71].
In  addition,  training  in  MRI-guided  vacuum-assisted  biop-
ies  with  histological  conﬁrmation  under  the  supervision  of
 specialist  is  required  before  a  practitioner  can  work  alone.
he  initial  training  involves  three  procedures  in  France  (as
ccess  to  MRI  is  still  limited)  [50,69]  but  15  procedures  are
equired  according  to  the  European  guidelines  [71].
Ten  procedures  per  site  per  year  are  then  sufﬁcient
50,64,69,71].
ontra-indications
he  contra-indications  are  those  of  MRI  (claustrophobia,
acemaker,  etc.),  contrast  medium  injections  (severe  renal
mpairment,  allergy)  and  biopsies  (reduced  coagulation,
llergy  to  anesthetic  agents)  although  these  are  gener-
lly  relative  and  can  be  managed.  Antiaggregants  with  a
a
b
t
sfound on MRI.
yclo-oxygenase  inhibitor  (Aspirine®)  or  adenosine  diphos-
hate  receptor  inhibitors  (Plavix®,  Ticlid®, Eﬁent®)  can  be
ontinued  [69—75].  An  initial  consultation  with  a cardiolo-
ist  or  anesthetist  in  patients  on  vitamin  K  antagonists  can  be
sed  to  consider  possibly  switching  to  low  molecular  weight
eparin,  otherwise  the  decision  is  based  on  the  International
ormalized  ratio  ([INR],  derived  from  the  prothrombin  time)
n  the  understanding  that  the  risk  of  bleeding  is  low  below
 and  high  above  3  [75,76].
One-pass  en  bloc  excision  with  radiofrequency  (Intact®)
annot  be  used  because  of  interference  with  the  electro-
agnetic  wave.
echnique
quipment
agnet
he  biopsy  is  generally  taken  in  a  closed  MRI  with  an  aver-
ge  ﬁeld  of  1  to  1.5  T  [11,13,25,27,28,58,60,63].  It  can
e  carried  out  in  a  high  ﬁeld  (3  T)  [63,67,77—80]  in  which
he  sensitivity  of  detecting  the  cancer  is  greater  for  the
ame  speciﬁcity  [81],  although  susceptibility  artefacts  are
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increased:  using  a  14G  needle  the  signal  vacuum  is  4  mm  at
1.5  T  [82]  and  9.5  mm  at  3  T  [77].
Open  machines  provide  easier  access  to  the  breast  and
real  time  monitoring  of  insertion  of  the  cannula.  Few  of
these  instruments  are  available  however  and  they  generally
use  a  low  ﬁeld  (0.2—0.5  T),  which  does  not  provide  sufﬁ-
cient  quality  imaging  [83],  although  this  is  still  a  possibility
[84—86].
Samples  are  therefore  taken  outside  of  the  magnet  to
avoid  image  distortion  from  the  needle  [87]  and  to  have  suf-
ﬁcient  space.  Interim  checks  are  made  in  the  tunnel  with
non-magnetic  materials  (introducer,  clip,  etc.)  to  reduce
risks  and  artefacts.
In more  general  terms,  non-magnetic  materials  should  be
used  in  preference  (forceps,  etc.)  and  ferromagnetic  mate-
rials  (scalpel,  needles,  gun,  etc.)  must  never  be  put  down
on  their  own  to  avoid  accidents  from  magnetic  attraction.
Coils
The  coils  should  if  possible  be  the  same  as  those  used  for
diagnosis  in  order  to  obtain  equivalent  performance.  It  must
be  possible  to  access  the  breast  to  take  the  samples,  which
assumes  that  the  coil  is  open.
The  initial  single  breast  coils  only  allowed  an  external
approach  and  therefore  required  the  practitioner  to  pass
through  the  entire  breast  for  internal  enhancement.
Current  dual  breast  coils  allow  either  external,  internal
or  even  superior  access  (InvivoM,  SentinelleM),  although  the
lateral  approach  should  be  preferred  as  this  is  the  most
straightforward  [46]  (Figs.  2  and  3),  using  a  soft  tipped  nee-
dle  if  necessary  in  order  to  avoid  the  risk  of  damaging  the
internal  skin  tissue.
Internal  access  is  limited  for  deep  lesions  and  is  incon-
venient:  the  contralateral  breast  lies  on  a  board  and  the
radiologist  works  from  beneath  in  a  tunnel,  when  a  non-
magnetic  lamp  may  be  very  useful  [46]  (Fig.  4).
MRI  images
Initial  and  then  dynamic  images  are  preferably  taken  in  high-
resolution  T1  weighted  3D  FS  echo  gradient  mode  [48].  The
acquisition  may  be  taken  through  axial  sections  although
resolution  is  often  better  in  sagittal  sections  [46].The  maximum  dose  (0.2  mL/kg)  or  a  half  dose  is
injected  depending  on  whether  or  not  a  repeat  end  of
procedure  injection  is  planned.  Unlike  other  countries
[13,27,31,32,88],  in  France  [46,50],  the  various  groups  do
g
r
t
Figure 3. a, b: external approach on a GE® coil.igure 2. Diagram showing access to an internal CE via a lateral
blue) and internal (red) approach.
ot  administer  a  further  injection  in  order  to  avoid  risk  of
aturating  or  missing  the  target  (small  or  poorly  vascularized
argets).
The  injection  rate  is  2—3  mL/s  and  the  contrast  medium
s  then  washed  out  with  20  mL  of  serum.
In  the  interim  views,  rapid  T1  spin  echo  (TSE)  [50]  images
re  preferable  in  order  to  reduce  needle  artefacts  [58].  The
E  is  often  poorly  visible,  in  which  case  anatomical  land-
arks  have  to  be  used.
The  principle  used  is  that  the  same  image  is  taken  on
our  occasions:  before  biopsy  (target  identiﬁcation),  after
ositioning  a  guide  (checking  correct  position  of  the  biopsy
ystem),  after  taking  the  biopsy  (conﬁrming  that  the  biopsy
avity  is  consistent  with  the  target)  and  after  positioning  the
lip  (checking  the  correct  position  of  the  marker)  (Fig.  5).
uiding  system
and  to  screen  guidance  can  be  used  for  identiﬁcations
84,89—91]  but  not  for  biopsies,  as  it  is  not  sufﬁciently  pre-
ise.
The  guidance  systems,  initially  incorporated  into  a  sin-
le  breast  dedicated  interventional  coil  [83,87,92], are  now
emovable  and  can  usually  be  incorporated  into  conven-
ional  diagnostic  coils.
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The  platform  may  consist  of  a  simple  frame  (MRI
evice®),  usually  combined  with  parallel,  ﬂexible,  vertical
r  horizontal  compression  bars  (Fig.  6).
This  is  linked  to  a  graduated  pillar  ﬁxed  to  the  coil  [77]
r  to  the  edge  of  the  MRI  bed,  equipped  with  rulers  to  set
he  x  and  y  coordinates  and  the  angulation  (Figs.  7 and  8).
The  grid  (General  Electric®)  is  now  the  most  widely  used
arget  system  (Fig.  3)  into  which  a  block  guide  is  inserted.
his  is  a  sterile,  multi-perforated  landmark  cube  through
hich  the  cannula  is  passed.  Regardless  of  targeting  method,
n  opaque  landmark  (a  tube  containing  gadolinium  [10],
 glycerin  cylinder  [46]  or  vitamin  E  capsule  [25])  is  ﬁxed
o  the  compression  plate.  The  end  of  this  is  positioned  in
ontact  with  the  breast  and  used  as  the  landmark  (refer-
nce  0  in  the  three  spatial  planes),  to  calculate  subsequent
argeting.  This  appears  as  an  obvious  hyperintensity  in  an
nenhanced  view  on  T1  weighted  images  (Fig.  5).
Targeting  software  (distances,  angles),  provided  either
n  the  landmark  identiﬁcation  kit  or  separately  depending
n  the  manufacturer,  are  particularly  useful  for  posterior
ontrast  enhancement.
CAD  can  highlight  the  CE,  from  the  subtraction  rather
han  from  the  unenhanced  image.  The  biopsy  system  used
s  recorded,  then  it  calculates  the  necessary  depth  taking
ccount  of  the  materials  and  thickness  of  the  cube.
iopsy  systems
ifferent  vacuum-assisted  biopsy  systems  are  used:
Atec® 9G  (Hologic  Inc,  Bedford,  MA)  [11,13,23,25,26,29,
34,63,93,94];
Vacora® 10G  (Bard  Biopsy  Systems,Tempe,  AZ)  [23,28,30,
31,33,57,59,60,88,95];
Senorx® 10G  (Bard  Biopsy  Systems,Tempe,  AZ)  [32,46];
Mammotome® 11G  (Devicor  Medical  Products,  Cincinnati,
OH)  [12,27,96—99].
These  systems  have  been  extensively  described  previ-
usly  [100—102]  and  have  been  adapted  to  MRI  with  speciﬁc
 m  cabling  and  vacuum  tubing  allowing  the  pump  to  sit
xternal  to  the  Faraday  cage.  Particularly,  long  probes  with
r  without  a  soft  tip  and  introduction  kits  comprising  of  a
lastic  cannula  and  two  styli  (non-ferromagnetic  metal)  are
sed  (Fig.  9).Large  diameter  cannulae  are  preferable,  with  a  mini-
um  requirement  of  11G  [50],  although  according  to  Fischer
imilar  results  can  be  obtained  with  9  and  10G  cannulae.
An  introducer  is  routinely  used  for  insertion  (Fig.  5).
e
t
s
iWith  coaxial  guns,  the  samples  return  through  the  can-
ula  and  are  recovered  outside  of  the  breast  (Mammotome®)
r  are  stored  in  a  small  posterior  container  (Atec®,  Senorx®,
ammotome®Revolve)  (Fig.  10).
Vacora® is  a  compact,  easily  transportable  system  and  is
ot  coaxial.  It  does  not  have  an  integral  system  for  sam-
le  collection  meaning  that  the  cannula  has  to  be  removed
or  each  sample  (Fig.  11).  This  causes  more  difﬁculty  from
lood  [31]  and  air  and  it  is  essential  to  use  a  support  for
he  gun  in  order  to  reduce  the  risk  of  displacing  the  can-
ula.  The  vacuum  aspirate  is  reported  to  be  less  powerful
nd  the  sampling  process  slower  (69  vs  39  minutes).  Coaxial
ystems  are  reported  to  be  able  to  biopsy  smaller  lesions  (10
s  19  mm),  faster  and  with  greater  conﬁdence  [103].
As  these  various  guns  are  non-magnetic  (Vacora® less  than
he  others),  they  are  not  attracted  by  the  magnet  although
nterference  with  their  operation  does  occur  if  they  come
oo  close  to  the  magnet.
he different stages [12,13]
reliminary  stage:  positioning  and  immobilization
he  patient  is  positioned  on  her  side  with  her  head  turned
o  the  opposite  side  and  her  arm  along  her  body  or  above
er  head  and  a  venous  line  with  long  connection  tubing  in
lace  (Fig.  12).
The  breast  is  wedged  in  the  surface  coil  and  the  guiding
ystem  is  set  up  from  the  beginning.  The  guide  mark  is  pos-
tioned  in  contact  with  the  skin  as  close  as  possible  to  the
rojection  of  the  CE  if  no  CAD  system  is  being  used  [46],  or
urther  away  in  order  to  avoid  hindrance  if  one  is  being  used
28].
The  breast  is  held  between  the  grid  and  an  often-solid
late.  Modest  compression  is  used  to  avoid  masking  the
nhancements  [83,104]  and  to  reduce  the  accordion  effect
decompression  of  the  breast  may  cause  displacement  of  a
lip  or  landmark  suture).
Accessibility  of  the  presumed  site  of  the  lesion  is  then
hecked  and  positioned  in  the  effective  grid  compression
rea.
tage  1:  targeting
he  patient  is  brought  into  the  magnet  and  an  initial
nhanced  image  is  taken  to  ﬁnd  the  CE  and  locate  it  against
he  guide  marker  (this  can  be  identiﬁed  by  the  presence  of
ilicone  or  parafﬁn  which  appears  as  a  T1  weighted  hyper-
ntensity  on  an  unenhanced  image)  (Fig.  5a,  b,  e).
MRI  vacuum-assisted  breast  biopsies  785
Figure 5. Patient with proven left breast recurrence referred for strategic biopsy of non-mass contrast enhancement located at the
junction of the internal quadrants of the right breast. The patient is positioned for an internal approach and MRI images are taken in sagittal
sections. Sagittal reconstruction MIP: a: stage 1: target identiﬁcation: the enhancement is located immediately behind the grid; b: new
stage 1: identiﬁcation of the target; after removal of the coil foams the CE projects onto the grid and becomes accessible; c: stage 2:
positioning an introducer; this is located on the posterior surface of the contrast enhancement; d: stage 5: post biopsy phase, visualization
of a hematoma of approximately a centimeter in size around the introducer in place of the initial enhancement. Axial reconstruction MPR:
786  R.  Plantade,  I.  Thomassin-Naggara
Figure 6. Guiding system: a: Device® MRI system. The introducer is in situ with its silicone sheath; b: Devicor® system. The ceramic
introducer is equipped with a window opening onto the sampling area.
Figure 7. Supports for the biopsy gun: a: with the Devicor®, system the dedicated gun is ﬁxed to the coil; b: the Siemens® system, this
occupies more space and is used as the support for the guide. It is ﬁxed to the examination bed.
F ystem
3
t
S
A
b
n
a
a
e
c
h
uigure 8. Sentinelle coil (Hologic®) with its grid and angulation s
Distances  are  measured  manually  or  by  software  in  the
 spatial  planes  between  this  reference  point  (‘‘zero’’)  and
he  abnormal  CE.tage  2:  positioning  the  introducer
fter  disinfection  and  local  anesthesia,  a  skin  incision  may
e  required  depending  on  the  shape  of  the  end  of  the  can-
ula.
t
b
s
: stage 1; f: stage 2; g: stage 2; h: stage 5; i: stage 5: this other ima
learly visible on the conventional T1 weighted echogradient images. Th
ematoma, which is a pronounced hyperintensity (as very recent). These
p the two ﬁlms provided in the summary.: a: frontal view; b: lateral view.
The  sterile  cube  is  then  inserted  into  the  grid,  possibly
fter  initially  tapering  the  introducer  on  the  cube,  which
llows  the  skin  incision  to  be  found  more  easily  [46]  (Fig.  13).
Depth  is  then  adjusted  taking  account  of  the  thickness  of
he  cube  and  adding  20  mm  for  Senorx®, 10  mm  for  Vacora®,
ut  nothing  for  Mammotome® [46].
Once  in  place  the  metal  sheath  is  replaced  with  a  silicone
heath  or  with  the  position  marker.  The  patient  is  returned
ge (axial T2*) may be useful to view the clip which is not always
e metal marker appears as a pronounced hypointensity inside the
 four stages of the biopsy in sagittal and axial images should make
MRI  vacuum-assisted  breast  biopsies  787
Figure 9. Fitting the materials to the MRI guide: a: the vacuum cabling and tubing are extended to keep the vacuum aspiration pump
(Devicor®) outside of the Faraday cage; b: Bard® introducing kit with a cannula and two sheaths (metal and silicone); c: the rounded end
of the cannula avoids damaging the covering skin.
Figure 10. Different means of recovering samples; a: with the Vacora®, non-coaxial system, the cannula is withdrawn from the breast to
recover each sample; b: with the Mammotome®, the samples are recovered as the procedure progresses through a window located outside
mens
r
1
aof the breast and in front of the gun; c: with the Encor®, the speci
inside  the  magnet  and  a  rapid  image  is  then  taken  to  check
the  correct  position  of  the  introducer.  The  biopsy  window  is
visible  on  the  Mammotome® cannula  (Fig.  5c,  f,  g,  6a).
Stage  3:  biopsy
The  introducer  is  replaced  by  the  cannula  and  then  a
series  of  samples  is  taken  (Fig.  11).  The  number  of  sam-
ples  depends  on  the  size  of  the  lesion,  cannula  diameter
and  quality  of  targeting.
f
1
p are stored in a container located at the back of the gun.
With  an  11G  cannula,  the  minimum  number  of  samples
equired  is  24  according  to  the  European  guideline  [64]  and
2  according  to  the  HAS  [50],  or  an  equivalent  volume  when
 larger  gauge  cannula  is  used  [62,64].
The  number  of  samples  reported  in  the  literature  rangesrom  2  to  75  [23,25,28,31,33,62,96,105]  with  a  median  of
2  [13,25,31,33,60,62,105].
The  samples  are  then  placed  in  a  bottle  and  sent  to  the
athologist,  together  with  the  full  radiological  and  clinical
788  
Figure 11. Large core biopsy with the Vacora® 10G, miniaturized,
non-coaxial system.
Figure 12. Patient positioning on their side with the breast
wedged in an open coil and the stereotactic guiding system pos-
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The  average  time  spent  in  the  MRI  is  approximately  1  hour
[50,63,87,106]: 20  [11]  to  70  minutes  [27,33,98].  This  is
F
ttioned from the beginning for a lateral approach.
etails,  which  are  absolutely  essential  for  MRI-guided  biop-
ies.  The  specimens  are  ﬁxed  and  then  at  least  three  sections
re  prepared.  They  must  be  read  by  an  experienced  breast
istologist  [33,34,50].
i
b
igure 13. Insertion of the introducer: a, b: the sheath is inserted int
he skin and the skin is then ﬁxed to the grid.R.  Plantade,  I.  Thomassin-Naggara
tage  4:  labeling  the  site
 clip  is  routinely  positioned  [13,25,26,33,46,50,54,60]  as
his  is  the  only  landmark,  which  can  be  used  to  guide  any
ubsequent  revision  surgery.
It  may  not  be  used  if  the  patient  refuses  [26],  if
ositioning  has  failed  or  if  one  is  not  applied  routinely
13,26,33,34,88].
It  is  positioned  through  the  cannula  before  the  cannula  is
emoved  or  after  the  check  image,  through  the  introducer.
tage  5:  end  of  procedure  check  image
he  patient  is  repositioned  in  the  tunnel  for  a  last  check
equence,  which  is  essential  [50].  This  is  used  to  determine
hether  the  contrast  uptake  has  reduced  or  disappeared
27,87],  although  it  is  often  sufﬁcient  to  check  that  the
iopsy  area  is  correctly  centered  on  the  initial  CE  (by
omparing  with  the  pre-biopsy  image)  and  that  the  clip  is
orrectly  positioned  (Fig.  5d,  h,  i).
This  sequence  is  carried  out  with  [13,27,31,32,88]  or
ithout  [46,50]  contrast  enhancement.
If  the  result  is  not  satisfactory  further  samples  should  be
aken  or  the  lesion  retargeted.
At  the  end  of  the  procedure,  the  patient  is  removed  from
he  tunnel,  placed  ﬂat  on  her  back  and  manual  compression
s  applied  followed  by  a  compressive  dressing.  Monitoring
or  half  an  hour  after  the  procedure  is  generally  sufﬁcient
50].
These  different  stages  are  illustrated  in  Fig.  14.
urationncreased  by  30  to  50%  [11,25,50,98]  when  two  sites  are
iopsied.
o the cube; c: the sheath assembled onto the cube passes through
MRI  vacuum-assisted  breast  biopsies  789
Figure 14. This is a 53-year-old patient who had intramammary silicone injections 20 years earlier and was then treated for right breast
cancer 2 years ago: a, b: mammography and ultrasound are difﬁcult to interpret because of the diffuse siliconomas; c: monitoring is therefore
mostly based on MRI which showed a relatively unsuspicious CE in the contralateral, supero-external quadrant suggestive of an intramammary
lymph node. A second look examination was negative and a repeat MRI was carried out 6 months later. This showed an increase in size of
790  
Figure 15. Non-magnetic trolley allowing pre and post biopsy pro-
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sedures to be carried out, outside of the room and therefore limiting
he time in the MRI room.
According  to  Norozian  [106],  the  length  of  the  procedure
epends  on  the  number  of  images  and  checks  in  the  tunnel,
hether  or  not  an  assistant  is  present  and  proximity  to  the
ipple,  as  this  is  reported  to  be  independent  of  patient  age,
ize  of  the  breast  and  type  or  size  of  enhancement.
The  MRI  room  occupation  time  can  be  reduced  with
rior  planning  the  positioning  and  venous  access  before
he  procedure  [106]  and  by  using  a  coaxial  system  [33]
r  even  a  second  non-magnetic  trolley.  This  enables  the
re-procedure  (positioning  the  materials  and  patient)  and
ost-procedure  activities  (removing  the  trocar,  compression
nd  dressing)  to  be  carried  out  outside  of  the  MRI  room.  The
ccupation  time  is  thus  reduced  by  approximately  a  third
Fig.  15)  to  35—39  minutes  [11,13,46,62].
Some  practitioners  even  take  the  samples  outside  of
he  room,  taking  advantage  of  this  approach  to  take  more
amples  (>  18)  to  reduce  underestimation,  although  they
osition  the  clip  at  the  beginning  of  the  procedure  and  do
ot  take  a  post-biopsy  check  image.
ocuments to be given out at the end of
he  procedure
he  patient  leaves  with  an  information  form  and  instruc-
ions,  a  provisional  report  and  images.  This  report  should
escribe  [69]:
the  clinical  context  of  the  biopsy;
the  lesion  (appearance,  with  BI-RADS  classiﬁcation,  size
and  site);
the  approach  route; ﬁ
he CE and guided ultrasound remained negative. The decision was th
xamination was performed in a sagittal acquisition with a grid system.
as seen again and was more intense and posterior. The mouse pointe
crolled through until the landmark cube was seen, placing the imprint
hen transposed to a diagram reproducing the lateral shape of the brea
his avoids errors moving from the position of the diagnostic images (sag
he biopsy position (patient lying down on her side/on the right). The x
he depth z. The section positions, CE and guide mark, can be subtract
 reformatted image taking care to position the marker on the theore
oorly seen in this axial section, followed by a dozen samples being take
he check image shows hemorrhagic changes hindering analysis of the re
howing a lymph node containing tumor.R.  Plantade,  I.  Thomassin-Naggara
the  materials  used;
the  samples  (number,  diameter)  [76];
traceability  of  the  materials  used  (cannula,  clip).
Images  should  be  provided  if  possible  in  all  the  three
patial  planes.
Four  summary  images  in  each  of  the  two  planes  (axial  and
agittal)  are  essential,  showing  the  initial  CE,  introducer  in
lace,  after  biopsy  and  the  clip  check  [46,50]  (Fig.  5).
Two  orthogonal  mammography  ﬁlms  of  the  breast
re  taken  to  check  the  correct  positioning  of  the  clip
46,50,64,69],  either  immediately  or  later  to  avoid  moving
t.
It  is  correctly  deployed  in  93  to  100%  of  cases
25,26,60,62]  and  failures  are  due  to  non-deployment  into
 superﬁcial  lesion,  bleeding  or  technical  error  [25,26].
Clip  positioning  was  correct  (<  10  mm)  in  79%  of  cases
eported  by  Malhaire  [68]  and  96%  reported  by  Siegmann
107],  with  an  average  distance  of  4.5  mm  [107].  Siegmann
107]  did  not  ﬁnd  any  secondary  drift  and  visualized  the  clip
orrectly  by  ultrasound  in  93.1%  of  cases  and  by  MRI  in  86.2%.
Despite  a  representative  sample  being  taken,  incorrect
lip  positioning  may  occasionally  result  in  repeat  biopsies
eeding  to  be  performed  [61].
imitations, difﬁculties and tips
f  MRI  is  contraindicated  or  technically  impossible,  the
ption  of  CT-guided  biopsy  should  be  considered  [108].
Strict  prolonged  immobilization  with  the  patient  on  her
ide  requires  good  patient  cooperation  from  50%  of  whom
nd  the  position  uncomfortable  [88].
Ten  to  25%  of  procedures  [27,57,58,97,109,110]  can-
ot  be  performed,  usually  because  the  CE  is  not  found
2  to  17%)  [23,25,27,30,31,33,38,57,63,80,97,98,110,111],
lthough  occasionally  because  of  obesity  [57,109,110]  or
ack  of  accessibility  [33,57,109].
The  CE  may  not  be  seen  because:
it  has  disappeared  because  of  excessive  compression  (in
which  case  a  further  image  should  be  taken  with  less
compression  of  the  breast)  or  if  the  initial  MRI  was  carried
out  at  the  wrong  time  of  the  menstrual  cycle  [97,111];
it  is  no  longer  clearly  identiﬁable  because  of  masking
of  the  enhancement,  small  size  (<  5  mm),  post-treatment
changes  or  limited  operator  experience  [46].
This  effect  is  as  common  with  high  ﬁelds  as  with  average
elds  [80].
en made to carry out MRI-guided vacuum-assisted biopsy; d: the
 The skin landmark was located on the lateral sections; e: the CE
r was placed on the enhancement as a landmark and the images
 of the grid on the skin on the section; f: the position of the CE is
st (in this case the CE is colored blue and the skin landmark red).
ittal sections shown upright on the console screen/on the left), to
 and y coordinates are then calculated on the grid. g. to establish
ed or the distance between the CE and skin measured directly on
tical external outline of the skin; h: the introducer is positioned,
n (9G caliber); i: a clip is positioned after the cannula is removed.
sidual CE; j: but the histological result is benign and in agreement
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It  is  then  possible  to  try  to  identify  it  using  neighboring
anatomical  structures  on  the  initial  diagnostic  MRI.
If  it  has  not,  however,  been  possible  to  take  biopsies,  a
repeat  MRI  without  compression  is  needed  within  24  hours
[46]  or  even  in  the  following  months  [97,111].  Viehweg
[97]  however  only  proposed  this  repeat  in  peri-menopausal
women  or  those  recently  started  on  HRT.  This  may  not  be
sufﬁcient,  as  whilst  the  malignancy  rate  for  these  CE  which
have  disappeared  on  the  day  of  biopsy  and  are  reviewed  sub-
sequently  was  zero  according  to  Han  [23]  and  An  [63],  the
corresponding  ﬁgure  was  2%  for  Thomassin  [46]  and  10%  for
Heﬂer  [111].
Like  the  other  guiding  methods,  retro-alveolar  or  super-
ﬁcial  lesions,  small  breasts  or  prosthetic  implants  (Fig.  10)
may  complicate  the  procedure  (compression,  accessibility
or  complication)  [58].
According  to  Malhaire,  2%  of  procedures  were  inaccessi-
ble  [33].
Cushions  can  be  added  for  small  breasts  or  the  breast
swollen  artiﬁcially  with  a  ‘‘wonder  bra’’  type  bandage
(elastoplast  applied  horizontally  or  vertically),  using  soft
tipped  cannulae  and  a  sampling  chamber  reducer  [46,47].
The  lateral  approach  should  be  used  in  preference  for
deep  lesions  in  order  not  to  be  impeded  by  the  sternum  [46].
The  patients  arm  can  be  positioned  along  her  body  and  the
foam  removed  from  the  coil  the  table  cushion  removed  and
the  opposite  side  of  the  patient’s  body  raised  to  bring  the
breast  down  into  the  coil  [46].
If  the  pectoral  muscle  is  prominent  an  attempt  should  be
made  to  ﬂatten  it  by  changing  the  position  of  the  arm  (along
the  body  or  above  the  head).
If  the  entrance  point  is  located  outside  of  the  grid,
the  procedure  can  be  performed  unguided  (free-hand
technique)  although  a  horizontal  path  is  not  guaranteed
[47,67,84,89,90].
Some  coils  (SentinelleM)  allow  the  grid  to  be  shifted,
maintaining  a  parallel  approach  to  the  wall.  Others  suggest
that  the  cannula  can  be  inserted  at  an  angle,  although  this
carries  a  risk  of  wall  damage  (pneumothorax,  etc.)  (Fig.  8).
Table  cushions  can  be  added  for  anterior  CEs  or  the  breast
thickness  increased  with  a  ‘‘wonder  bra’’  bandage.
If  a  prosthetic  implant  is  present,  this  should  be  pushed
aside  and  the  cannula  positioned  on  the  anterior  surface  of
the  CE:
• the procedure  should  be  performed  relatively  soon  after
the  gadolinium  injection  (<  15  minutes)  as  malignant
lesions  ‘‘wash  out’’  [46]  and  the  neighboring  tissues
enhance  [47,83].  The  blood  hyperintensity  contributes  to
masking  the  CE;
• patient  magnetic  susceptibility  and  magnetic  ﬁeld  distort-
ions  due  to  the  coil  and  metal  needles  may  cause  ballistic
approximations  because  of  needle  drift  [55]  or  the  lesion
being  pushed  aside  [83].  Large  caliber  needles  also  cre-
ate  a  signal  void  proportional  to  their  diameter  which  is
reduced  with  MRI  compatible  needles  [55]  and  may  mask
the  enhancement  and/or  tip  of  the  needle  [55,83,112].The  clip  causes  a  magnetic  susceptibility  artefact,  which
is  seen  on  the  ﬁnal  images.  Air  inside  the  biopsy  cavity  also
generates  a  signal  void,  which  can  cause  identiﬁcation  errors
[47].
s
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As  less  compression  is  applied  than  for  stereotaxis,  the
isk  of  the  lesion  being  pushed  aside  is  greater  but  the  accor-
ion  effect  and  therefore  the  risk  of  incorrectly  positioning
he  clip  is  less.
El  Khouli  [113]  found  an  average  overall  ballistic  error  in
he  space  of  4.4  mm  on  a  model  and  5.7  mm  on  patients,
ndependently  of  operator  if  a  protocol  is  present  and  fol-
owed  and  concluded  that  CE  are  accessible  up  to  5—6  mm.
n  order  to  improve  the  reliability  of  MRI-guided  biop-
ies  some  therefore  recommend  preferentially  biopsying
nhancements  of  over  5  mm  [8,114],  or  even  10  mm  [4,8],
iven  that  contrast  enhancement  of  under  5  mm  is  usually
enign  [24,115]. Perlet  [27], however,  felt  that  vacuum-
ssisted  biopsy  performed  well  and  was  particularly  useful
or  small  lesions  as  the  larger  ones  were  generally  visible  on
ltrasound.
Several  pitfalls  limit  the  diagnostic  conﬁdence  compared
o  what  is  achieved  with  mammography  or  ultrasound  guided
iopsies  [46,47,58]:
there  is  no  check  with  a  cannula  in  situ, and  even  less  in
real  time;
the sampling  radiographs  are  of  no  use  if  they  contain  no
calcium  or  ﬁbrous  signal;
pathologists  have  no  calciﬁed  or  nodular  lesion.
anagement of the result
echnical success
ccording  to  Crystal  [34], the  distance  between  the  cannula
nd  CE  must  not  be  more  than  3  mm.
Success  is  assessed  particularly  however  from  the  reduc-
ion  or  disappearance  of  the  CE.
Perlet  [27]  and  then  Tosaki  [116]  referred  to  success  if
he  enhancement  was  reduced  by  at  least  50%.
According  to  Hauth  [31]  and  Ghate  [60], a partial  unquan-
iﬁed  reduction  is  sufﬁcient  whereas  most  authors  do  not
eport  their  criteria  for  success.
The  assessment  is  hindered  by  bleeding  in  9  to  38%
f  cases  [60,63,87],  air,  the  anesthetic  agent  and  move-
ents  [47,57,117].  In  this  situation,  Perlet  [27]  carries  out
 repeat  MRI  2  to  4  days  after  the  procedure.  Hauth  [31]
ven  routinely  replaces  the  check  sequence  at  the  end
f  the  procedure  with  an  MRI  24  hours  later  in  order  to
ptimally  assess  whether  the  procedure  is  representative
nd  uses  this  to  explain  her  lower  success  rate  than  other
eries.
According  to  Perlet,  success  does  not  depend  on  the  size
f  the  CE  or  the  experience  of  the  radiologist  [27].
Malhaire  [33]  however  described  failures  and  missed  can-
ers  during  the  initial  learning  period.
Enhancements  of  4  and  100  mm  are  reported  in  the  lit-
rature  with  an  average  of  10  mm  [11,13,25,26,33,60,63,
05,113]. These  disappeared  in  33.1%  of  cases  (4—81%),
educed  in  59.6%  (18—87%)  and  were  unchanged  in  7.3%
0—30%)  [25,27,29,31,60,87,88,116,118]  (Table  3).Complete  excision  rates  for  the  radiological  signal  are
imilar  to  those  achieved  with  stereotactic  biopsies  (≈  38%)
102,119]  and  less  than  those  with  ultrasound-guided  proce-
ures  (>  70%)  [100,101].
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Table  3  Assessment  of  success  of  vacuum-assisted  biopsy  based  on  the  change  in  CE.
Authors  references  Year  No  change  (%)  Partial  resolution  (%)  Completely  disappeared  (%)
Heywang  [87]  2001  1  87  12
Liberman  [25]  2005  4  66  29
Ghate  [60]  2006  30  65  5
Perlet  [27]  2006  4
Lee  [29] 2007  1  69  30
Tozaki*  [116] 2007  0  40  60
Hauth  [31] 2008  13.8 72.4 13.8
Perretta  [88]  2008  4
Ferré  [118]  2011  1  18  81
An  [63]  2013  0  87.5  12.5
Mean  6.4  63.1  25.1
*Only ﬁve patients.
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sThe  average  size  of  the  CE,  which  completely  disap-
eared  however  was  13.9  mm  according  to  Ferré  [118].
Failures  are  uncommon  (0  to  14%)  [11—13,25—27,30—33,
6,60,62,96—99,118,120,121]  and  are  due  to  inadequate  or
iscordant  samples  [25—27,58,87,110].
These  may  be  due  to  patient  reactions  (malaise  or
nxiety)  [25—27],  technical  difﬁculty  with  the  materials
cannula  or  table),  patient  (accessibility,  breast  too  thin)
26,27,60],  or  operator  [27],  or  bleeding  [46].
According  Imschweiler  [121],  therefore,  the  success  rate
s  similar  to  that  achieved  with  stereotactic  biopsies  and
ower  than  that  achieved  with  ultrasound-guided  proce-
ures.istological result
he  distribution  of  histological  results  varies  greatly  depend-
ng  on  recruitment  for  breast  MRI.  Benign  results  are  found
1
o
o
Table  4 Context  in  which  the  MRI-guided  vacuum-assisted  bi
sponding  malignancy  rate  (in  brackets).
Authors
[references]
Year Pre-treatment
assessment  (%)
Post-treatment
follow  up  (%)
Liberman  [25]  2005  23  (27)  9  (25)  
Lehman  [11]  2005  61  24  
Orel  [26]  2006  54  15.3  
Perlet  [27]  2006  8  (36)  29  (32)  
Plantade  [28]  2006  40  (50)  10  (100)  
Lee  [29]  2007  31  10  
Gebauer  [30]  2007  29.4  2.4  
Han  [23]  2008  41  (36)  16  (23)  
Hauth  [31]  2008  18.2  39.4  
Mahoney  [32]  2008  21  38  
DeMartini  [21]  2009  26  10  
Malhaire  [33]  2010  13  32  
Crystal  [34]  2011  8  39  
(): malignancy rate.n  18  to  74%  of  cases  [11,13,25—28,60,87,89,98,99],  border-
ine  in  1  to  21%  [11,13,25,26,28,60,87,97—99]  and  malignant
n  5  to  61%  [11—13,25—28,46,60,87,96—99,120].
The  PPV  ranges  from  5  to  100%,  [13,25—27,
0,31,33,38,60,63,96,98,121]  and  the  NPV  is  over  93%
27,38,121].
If  the  indications  for  MRI  are  correctly  followed,  however,
he  malignancy  rate  is  over  20%,  which  justiﬁes  the  samples
eing  taken  (Table  4).
According  to  Gebauer  [30],  the  malignancy  rate  was  4.5%
1/22)  for  BI-RADS  3,  44.4%  (8/18)  for  BI-RADS  4  and  100%
2/2)  for  BI-RADS  5.
This  is  reported  to  be  higher  in  diagnostic  compared  to
creening  examinations  (personal  history,  high  risk)  (32  vs
2%)  [23,122]  and  for  CE  with  a  mass  appearance  or  wash
ut  [62,122].
Han  [23],  however,  reported  that  this  rate  did  not  depend
n  either  the  time  or  the  kinetics  of  the  CE.
opsies  were  performed:  distribution  by  series  and  corre-
High  risk  family
(%)
Suspicious
mammography
Other indications
(%)
Abnormality  on
one  view  (%)
46  (19)  21  (45)
15
30.7
11.4  (27)  21.9  (20)  29.7
50  (40)
34  24
68.2
13  (28)  30
9.1  33.3
41
22  16  26
32  25
38  15
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Mass  CE  are  more  often  malignant  [46]  and  are
usually  due  to  inﬁltrating  carcinoma  (64%)  [22,25]
whereas  non-mass  CE  are  due  particularly  to  DCIS  (80%)
[25].
Discordances
There  are  two  types  of  discordance:
• site:  the  biopsy  area  is  located  distant  to  the  CE;
• histology:  the  result  is  unexpected  in  light  of  the  CE  BI-
RADS  appearance.
Concordant  benign  samples  make  up  0  to  12%  of  cases
[11,13,23,25,26,28—30,32,60,61,88,96,123]  with  a  mean  of
5.3%  [23,25,26,29,30,32,33,118]  and  the  malignancy  rate
ranges  from  0  [43,65]  to  100%  [26,28,30]  with  a  mean  of
44.5%  [23,25,26,29,30,32,33,118]  (Table  5).
These  results  are  similar  to  stereotactic  or  ultrasound-
guided  biopsies.
In  Lee’s  study  [122],  the  CE  was  reduced  in  71%  of  dis-
cordant  cases  although  the  malignancy  rate  in  this  situation
was  27%.  This  highlights  the  importance  of  checking  radi-
ological  and  histological  concordance,  [25,26,69,123]  and
justiﬁes  a  further  biopsy  (percutaneous  or  surgical)  of  dis-
cordances  [123],  rather  than  a  repeat  MRI  after  6  months
[61].
Similarly,  insufﬁcient  samples  should  be  repeated.
Final report and conclusion (Fig. 1)
Once  the  histopathological  diagnosis  has  been  received,  a
summary  of  the  results,  their  concordance  and  future  man-
agement  should  be  included  in  the  report  [69].
For  concordant  benign  lesions  authors  recommend
a  repeat  routine  MRI  in  6  to  12  months  [10,11,25,
58,60,63,64,87],  or  even  in  3  to  6  months  according  to  the
HAS  working  group  [46,50],  bearing  in  mind  the  limitations
of  this  follow-up  [61].
Revision  surgery  is  required  for  carcinomas  or  borderline
lesions  [27,34,50].
Finally,  all  cases  [33,64]  or  at  least  ambiguous  cases  [69]
should  be  discussed  in  the  MDT.
In  this  situation,  most  authors  do  not  report  any  missed
cases  of  cancer  [25,27,31,32,87,88,95].
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Table  5  Discordance  frequencies  with  their  associated  malign
Authors  [references]  Year  Number  of  lesions  Discorda
Liberman  [25]  2005  112  9  (9%)  
Orel  [26]  2006  85  2  (2.4%
Lee  [29]  2007  342  24  (7%)  
Mahoney  [32]  2008  55  3  (11%)
Gebauer  [30] 2008  42  1  (2.4%
Han  [23] 2008  90  1  (0.9%
Malhaire  [33] 2010  72  3  (4%)  
Ferré  [118]  2011  146  7  (4.8%
Total  944  50  (5.3%793
The  HAS  working  group  [50], however,  estimated  a  missed
iagnosis  rate  of  1—2%  compared  to  2.3%  according  to  Li
61], which  is  still  acceptable.
nderestimations
hese  are  due  to  undergrading  of  the  histological  lesion  (ADH
s  DCIS,  borderline  or  DCIS  vs  inﬁltrating  carcinoma)  and  are
eported  overall  to  occur  in  4  to  19%  of  cases  [23,38,96]
Table  6).
Figures  range  from  11  to  50%  for  all  borderline
esions  [23,25,26,33,34,46,60,106,122],  with  a  mean  of  28%
23,33,34,46,106,122].
Brennan  [79]  published  a  large  series  of  1487  MRI-guided
acuum-assisted  biopsies,  with  a  5%  papilloma  rate.  Quasi-
outine  surgical  revision  (67/75)  found  underestimations  of
%  for  papillomas  without  atypia  and  9%,  when  atypia  was
resent.  This  is  relatively  similar  to  ultrasound-guided  pro-
edures  [129].
ADH  represents  4  to  11%  of  biopsies  and  has  an
verage  underestimation  rate  of  32.4%  (13—100%)
11,26,27,32—34,60,88,94,95,118]  (Table  7),  which  is
wice  that  of  stereotactic  procedures  [113,121].
No  predictive  indicators  have  been  identiﬁed  to  reduce
he  underestimation  rate  for  ADH  [94]  or  for  borderline
esions  more  generally  [34].
Underestimations  for  DCIS  range  from  0  to  25%,
ith  an  average  of  10.3%  [11,23,25—27,29,33,88,95,99]
Table  8),  which  is  relatively  similar  to  stereotactic  biopsies
27,119,129]  or  ultrasound-guided  biopsies  [100].  Lee  [29]
ound  a  signiﬁcant  increase  in  underestimations  when  pos-
ible  concomitant  microinﬁltration  was  present  (17  vs  80%),
lthough  found  no  other  predictive  indicators  (size,  excision,
tc.).
Like  the  stereotactic  biopsies,  underestimations  of  ADH
ppear  therefore  to  occur  more  commonly  than  with  DCIS.
omplete excision of the carcinoma
omplete  percutaneous  excision  of  the  carcinoma  has  been
eported  in  0  to  25%  of  cases  with  an  average  of  13%
11,19,23,25,27,29,31,33,46,88,105,118]  (Table  9).
According  to  Perlet  [27],  this  only  involved  lesions  under
 centimeter  in  size.
ancy  rates.
nce  Number  of  surgical  cases  Cancers  and  surgery
8  4  (50%)
)  2  2  (100%)
20  6  (30%)
 2  0  (0%)
)  1  1  (100%)
)  1  0  (0%)
3  2  (66.7%)
)  7  5  (71.4%)
)  44  20  (44.5%)
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Table  6  Distribution  and  results  of  MRI-guided  core  and  vacuum-assisted  biopsy  punctures.
Type  of
procedure
Authors  and
references
Needle
diameter
Gauge
Year  Number  of
lesions/patients
Size Benign  Borderline
Pre-operative
localization
Kuhl  [104]  1997  97/66  44  (45%)
Daniel  [89]  20/21  1998  19/17  0.9  (0.3—6)  11  (58%)
Fischer  [8] 1998  132  68  (52%)  0  (0%)
Orel  [124] 20  1999  137  1.2  (0.3—7)  80  (58%)
Smith  [59] 22  2001  16/16  11  (69%)
Lampe*  [125] 2002  132  0.9  62  (47%)
Bedrosian  [126]  2002  41/41  22  (54%)
Morris  [5]  18/20  2002  101/69  1.1  (0.2—8)  61  (60%)  9  (9%)
Taourel*  [127]  2002  264  169  (64%)
Fine  needle
aspiration
cytology
Wald  [128]  22  1996  18/16  1.8  (1—3.6)  16  (89%)
Fischer  [8]  19.5  1998  31  24  (77%)  0  (0%)
Core  Smith  [59]  16  2001  25/23  20  (80%)
Biopsy  Daniel  [84]  2001  27/19  18  (67%)
Kuhl  [82]  14  2001  78/59  1.5  (0.6—3)  50  (64%)
Schneider  [85]  14  2002  21/21  (0.5—1.7)  13  (62%)
Chen  [10]  14  2004  35/29  1.5  (0.3—7)  21  (62%)  5  (15%)
Vacuum  Viehweg  [12]  11  2002  280  208  (74%)
Biopsy  Perlet*  [98]  11  2002  341  233  (68%)  24  (7%)
Heywang  [87]  11  2002  87/80  63  (73%)  1  (1%)
Orel  [120]  12  2003  9/8  5  (56%)
Liberman  [25]  9  2005  98  1  (0.4—8.5)  52  (60%)  10  (12%)
Lehman  [11]  9  2005  38/28  1.1  (0.2—7)  22  (58%)  2  (5%)
Wiehweg  [97]  11  2006  97/63  62  (71%)  4  (5%)
Perlet*  [27]  11  2006  538  (0.3—2.1)  362  (70%)  17  (3%)
Orel  [26]  9  2006  95/75  1.7  (0.5—10)  15  (18%)  18  (21%)
Ghate  [60]  10  2006  20/19  0.8  (0.4—2)  14  (74%)  4  (21%)
Plantade  [28]  10  2006  10/10  0.8  (0.4—7)  5  (50%)  0  (0%)
Gebauer  [30]  10  2006  42/32  0.9  (0.3—2.3)  28  (67%)  3  (7%)
Liberman  [94] 9  2007  237  156  (66%)  37  (16%)
Lee  [29] 9  2007  373  306  (82%)
Tozaki  [116]  11  2007  30  1.6  (0.5—2.5)  4  (80%)  1  (20%)
Perretta  [88]  10  2008  47/47  0.9  28  (60%)  4  (8%)
Han  [23]  10  2008  172/154  1.5  (0.4—7)  90  (60%)  21  (14%)
Hauth  [31] 10  2008  29  1.3  (0.5—3.2)  20  (69%)  0  (0%)
Mahoney  [32]  10  2008  55/47  <1  (—3.7)  38  (69%)  7  (13%)
Fischer  9/10  2009  389/365  231  (59%)  50  (13%)
Malhaire  [33]  10  2010  72  1.2  (0.4—7)  29  (40%)  10  (14%)
Oxner  [95]  10  2012  187/127  (0.4—1.2)  126  (68%)  16  (9%)
Imschweiler*[121]  2013  557  283  (54%)  107  (20%)
Cancer Underestimation Complications Time  in
minutes
Success
ADH  DCIS
53  (55%)  40  (30-60)  95  (98%)
8  (42%)  1  (5%)  64  (≤90)  19  (100%)
64  (48%)  (30-60)  127  (98%)
57  (42%)  134  (98%)
5  (31%)  3  (19%)  16  (100%)
70  (53%)  3  (2%)  127  (96%)
19  (46%)  41  (100%)
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Table  6  (Continued  )
Cancer Underestimation Complications Time in
minutes
Success
ADH  DCIS
31  (31%)  3  (3%)  31  (15-59)  101  (100%)
95  (36%)  259  (98%)
2  (11%)  42  (30-80)  11  (61%)
7  (23%)  (30-60)  28  (90%)
5  (20%)  0  (0%)  24  (96%)
9  (33%)  70  (55-90)  27  (100%)
28  (36%)  1  (2%)  60  (45-100)  77  (99%)
8  (38%) 45 (40-65) 20  (95%)
8  (23%) 2  (40%) 1  (100%) 0  (0%) 34  (97%)
72  (26%)  >60  277  (99%)
84  (25%)  (18%)  0  (0%)  16  (5%)  (70-90)  334  (98%)
22  (26%)  >60  86  (99%)
4  (44%) 9 (100%)
24  (28%) 2  (50%)  1  (11%)  6  (6%)  33  (17-60)  95  (97%)
14  (37%) 1  (50%)  1  (25%)  0  (0%)  50  (39-61)  38  (100%)
19  (24%)
138  (27%) 5  (29%) 3  (4%) 27  (5%)  70  517  (96%)
52  (61%) 2  (25%) 4  (24%)  0  (0%)  (30-60)  83  (98%)
1  (5%) 1  (33%) 0  (0%) 5  (26.3%)  19  (95%)
5  (50%) 0  (0%) 70  9  (90%)
11  (26%) 0  (0%) 32  (100%)
44  (19%) 5  (38%)
67  (18%) 5  (17%)
0  (0%) 48 (30-60) (100%)
15  (32%)  1  (25%)  1  (14%)  2  (4%)  47  (100%)
39  (26%)  5  (19%)
9  (31%)  4  (14.3%)  65  (52-87)  25  (86%)
10  (18%)  2  (67%)  0  (0%)  2  (4%)  55  (100%)
106  (28%)  (<1%)  43  (17-95)  38  (100%)
33  (46%)  1  (100%)  2  (22%)  3  (3%)  72  (50-131)  69  (96%)
44  (23%)  2  (13%)  0  (0%)  0  (0%)
137  (26%)  20  (19%)  38  (7%)  548  (98%)
(): range; *: multicenter study.
Table  7  Underestimation  for  atypical  ductal  hyperplasia.
Authors  references Year Number  of  ADH Number  of  carcinomas  on  surgery  Underestimation  (%)
Diagnosed  Operated
Lehman  [11]  2005  2  2  1  50
Orel  [26]  2006  8  8  2  25
Perlet  [27]  2006  17  17  5  29
Ghate  [60]  2006  2  2  1  50
Liberman  [94]  2007  15  13  5  39
Perretta  [88]  2008  4  4  1  25
Mahonay  [32]  2008  3  3  2  67
Malhaire  [33]  2010  7  1  1  100
Crystal  [34]  2011  7  6  3  50
Ferré  [118]  2011  9  9  3  33
Oxner  [95]  2012  15  15  2  13
Total  80  71  23  32
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Table  8  Underestimation  for  ductal  carcinoma  in  situ.
Authors  references Year Number  of  DCIS Number  of  inﬁltrating
carcinomas  on  surgery
Understimation
(%)
Diagnosed  Operated
Liberman  [25]  2005  13  11  1  9
Lehman  [11] 2005  4  4  1  25
Orel  [26] 2006  17  17  4  24
Perlet  [27] 2006  64  64  3  5
Lee  [29]  2007  29  29  5  17
Han  [23]  2008  15  10  1  10
Perretta  [88]  2008  7  7  1  14
Tozaki  [99]  2010  28  28  3  11
Malhaire  [33]  2010  9  9  2  22
Oxner  [95]  2012  25  25  0  0
Total  211  204  21  10
Table  9  Frequency  of  complete  percutaneous  excision  of  the  malignant  tissue.
Authors  references Year No. of  cases  in  which  no  residual  tumour  was  found  on
revision  surgery
Ductal  carcinoma  in  situ  Inﬁltrating  carcinoma
Lehman  [11]  2005  −2/13  (15.4%)
Liberman  [25]  2005  2/11  (18.2%)  2/9  (22.2%)
Orel  [19]  2006  4/17  (25.5%)  3/30  (10%)
Perlet  [27]  2006  13/64  (20.3%)  6/74  (8.1%)
Lee  [29]  2007  5/34  (14.7%)
Peretta  [88]  2008  2/8  (25%)
Han  [23]  2008  0/18  (0%)  0/25  (0%)
Lee  [105]  2008  −12/67  (18%)
Hauth  [31]  2008  −1/9  (11%)
Malhaire  [33]  2010  1/5  (20%)  4/17  (23.5%)
Ferré  [118] 2011  −4/45  (8.9%)
Thomassin  [46]  2011  −0/19  (0%)
An  [63] 2013  −1/3  (33.3%)
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And  Lee  [105]  reported  that  the  complete  excision  rate
ncreased  if  the  lesion  was  under  a  centimeter  in  size  (28  vs
%)  or  if  the  CE  completely  disappeared  (36  vs  9%).
Like  stereotaxis  [130]  or  ultrasound  [131,132]  no  factors
uch  as  disappearance  of  the  radiological  ﬁnding,  currently
onﬁrm  that  no  residual  tumor  is  present,  although  this
ould  be  useful  in  considering  additional  local  treatments
uch  as  focused  ultrasound.
omplications
he  morbidity  of  MRI-guided  vacuum-assisted  biopsy  is  low
nd  ranges  from  0  to  6%  [11,13,25—27,30,57,100].  This  is  a
imilar  rate  to  stereotactic  procedures  and  higher  than  for
ltrasound-guided  biopsies  [121].
Complications  (hematomas,  malaise,  skin  damage)  are
enerally  minor  [25,26,30].
Ten  percent  of  procedures,  however,  have  to  be  stopped
ecause  of  adverse  effects  (heavy  bleeding,  malaise,  hyper-
entilation,  etc.)  [46].
a
I
s
[ (13.1%)
Bleeding  requiring  surgery  only  occurs  in  less  than  1%  of
rocedures  [25—27,30,33,87].
omparison with other MRI-guided
rocedures
reoperative  landmarking,  aspirations  and  core  biopsies  are
ess  aggressive  procedures,  which  use  more  readily  available
nd  less  expensive  equipment.
Pre-operative  localization,  however,  is  the  ﬁrst  stage  of  a
urgical  procedure,  which  is  of  debatable  utility  for  a  poten-
ially  benign  lesion.  Vacuum-assisted  biopsy  is  therefore  an
ttractive  alternative  [4,5,8,12,20,26]. Fine  needle  cytol-
gy  aspiration  often  returns  insufﬁcient  material  for  the
iagnosis  [96,128].
Core  biopsies  produced  good  results  [10,82,104,133,134]
lthough  the  needle  has  to  be  removed  for  each  sample.
t  is  reported  to  be  faster  than  vacuum-assisted  biop-
ies  but  inadequate  for  lesions  under  a  centimeter  in  size
8,58,87,135].
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The  success  rates  for  core-  [10,30,77,80,82,83,134,136]
and  vacuum-assisted  biopsies  [11,25,26,62,78,98,103,137]
are  reported  to  be  similar  (>  93%)  although  vacuum-assisted
biopsies  are  reported  to  have  a  better  representivity  rate
[78]  (Table  7).
The  authors  therefore  recommend  that  unless  unavail-
able  or  technically  impossible,  vacuum-assisted  biopsy  be
used  in  preference  [78,138,139].
Tariff and accessibility
MRI-guided  vacuum-assisted  biopsies  do  not  currently  have
any  speciﬁc  code.
Only  item  QEHJ006  (=  percutaneous  mammary  gland
biopsy  with  remnographic  guidance)  exists.  This  is  MRI-
guided  core  biopsy  and  carries  a  tariff  of  76.80  Euros  to
which  the  breast  MRI  tariff  can  be  added.  This  is  consider-
ably  less  than  the  cost  of  the  vacuum-assisted  biopsy  cannula
and  the  MRI  time  required.
This  applies  even  more  to  dual  procedures  as  the  exami-
nation  time  is  increased  and  two  cannulae  are  recommended
[50].
In  order  not  to  lose  out  ﬁnancially,  some  apply
the  stereotactic  vacuum-assisted  biopsy  tariff  (QEHH002:
511.68  Euros)  or  the  tariff  for  a  day  hospital  admission.
The  reimbursement  ﬁle  was  however  submitted  to  the
HAS  in  July  2009  and  the  technical  assessment  report  was
published  in  December  2011,  although  this  procedure  is  still
not  included  in  the  French  Joint  Classiﬁcation  for  Medical
Procedures.
The  tariff  for  a  vacuum-assisted  biopsy  in  the  USA  and
Australia  is  the  same  regardless  of  type  of  guiding  used.
In  addition,  despite  the  recent  approvals  for  MRI,  in
France  the  numbers  of  instruments  available  are  still
far  below  those  in  its  European  neighbours,  particularly
since  MRI  screening  for  at  risk  women  has  been  intro-
duced.
Access  to  interventional  MRI  is  therefore  still  restricted
and  far  less  open  than  in  other  western  countries,  although
the  country  is  gradually  equipping  itself  through  technolog-
ical  advances  (coils,  biopsy  systems  etc.)  and  investments
from  the  different  parties  involved.  Only  43  procedures  were
recorded  in  2006  and  of  the  200  French  sites  where  breast
MRI  was  being  performed  in  2009,  36  had  an  interventional
breast  coil  and  14  were  using  it  (survey  by  the  Société
franc¸aise  de  radiologie  —  Société  franc¸aise  de  mastologie  et
d’imagerie  du  sein).  At  least  20  procedures  were  carried  out
per  year  in  four  centers  and  a  maximum  ten  in  the  other
centers.
The  ﬁve  main  centers  currently  carry  out  an  average  of
around  ﬁfty  procedures  annually.
According  to  the  HAS,  the  target  population  is  100  to
700/year  (this  number  was  obtained  from  the  annual  activity
of  the  14  reference  centers)  [50].
Some  recommend  that  all  sites  where  breast  MRI  is  per-
formed  also  offer  MRI-guided  vacuum-assisted  biopsies  [47],
although  currently  this  appears  unrealistic  in  France  and  the
aim  is  rather  that  these  sites  collaborate  with  a  neighbor-
ing  center  where  the  different  MRI  guided  procedures  are
performed  [50].797
onclusion
RI-guided,  vacuum-assisted  biopsy  has  remained  a  con-
dential  home-grown  technique  for  years  [7,89,92,140],
eserved  for  some  centers  only  as  it  is  a  time  consuming
xamination  with  very  limited  indications  and  no  speciﬁc
ariff  in  France.
In addition,  the  lack  of  a  radiological  image  to  conﬁrm
hat  the  samples  were  representative  and  the  radio-
istological  correlation  clearly  raise  technical  difﬁculties.
Despite  these  various  limitations,  it  is  a  major  technique,
hich  can  optimize  the  information  provided  by  breast  MRI,
n  essential  condition  for  it  to  develop  [96].
Major  technical  advances  (coils  and  software,  etc.)  have
ncreased  reproducibility  in  recent  years.  This  is  now  a  vali-
ated  technique  offering  high  levels  of  concordance  and  low
nderestimation  rates,  which  is  reserved  mostly  for  special-
st  centers  [50].
Tools  such  as  spectroscopy  and  high  ﬁelds  may  in  the
uture  increase  the  speciﬁcity  of  MRI  allowing  better  selec-
ions  of  lesions  to  be  biopsied  and  the  detection  of  possible
ost-biopsy  residual  tumor.
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